Ranolazine
DrugRanolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Other names: Ranexa
NCT Number: NCT02829034
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF <45%) will improve their health by improving right ventricular (RV) function.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
University of Maryland, Baltimore, Maryland, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Other names: Ranexa
Placebo by mouth twice per day for a total of 26 weeks
Time frame: 26 weeks
Change in right ventricle ejection fraction as assessed by MRI
Time frame: 6 months
6-minute walk test
Time frame: 6 months
NT-proBNP measured at 6-months compared to baseline
University of Pennsylvania
Other
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00011648
Anemia, Anemia, Hemolytic
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00678821
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT03629340
Cardiovascular Diseases, Heart Diseases
San Francisco, California, United States
View Trial DetailsNCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial Details